Radiation exposure has become an important concern for human beings in everyone\'s daily life, because a person may receive irradiation from many different sources. For example, radiological weapons are able to cause radiation exposure to many people in a short time even if they are only small dirty bombs. A nuclear power plant may change into a dangerous radiation source when natural disasters happen, such as the devastating tsunami in Fukushima in Japan. In such cases, a large number of people will receive different amounts of radiation exposure and suffer a corresponding variety of ill effects.

Several literature reports have shown that distinct biological functions and damage patterns are triggered in cells in response to different doses of ionizing radiation (IR)[@b1][@b2][@b3]. Therefore, how to estimate the radiation exposure of IR-treated samples, which is called radiation dosimetry, has become a critical and urgent issue.

Several methods have been developed for assessing the radiation doses received by exposed samples[@b4][@b5][@b6], but their applications may be limited in a severe radiation emergency. For instance, the dicentric assay requires much effort and at least three days to be completed[@b6][@b7]. Another popular approach is to observe the declining lymphocyte counts in the first 48 hours after irradiation[@b4]; however, such measurement still takes at least two days to be done, which may make it difficult to be used in a large-scale radiation emergency. Therefore, developing a new methodology to assess radiation exposure in tissue samples more quickly is necessary and beneficial for future applications.

With the advancement in high-throughput technologies, data from DNA microarrays and next-generation sequencing provide a good basis to address this issue. In recent years, several studies have demonstrated the success and effectiveness of predicting radiation doses based on gene expression levels[@b7][@b8][@b9]. For example, Paul et al. identified a 74-gene signature that can be utilized to predict four radiation doses from human peripheral blood[@b7], and Dressman et al. reported a 25-gene signature to classify irradiated human samples based on the radiation doses[@b8]. Such studies had high prediction accuracies within their own datasets; however, challenges arise when trying to validate the predictions in independent datasets.

It is well known that biomarkers identified in one microarray dataset are usually irreproducible across studies, even if the investigated samples have similar clinical parameters[@b10][@b11]. The reasons for such high inconsistency in identified biomarkers across datasets may be attributed to different microarray platforms, various experimental protocols, and dissimilar statistical approaches. Consequently, the practical application of the identified biomarkers is limited. One possible approach to address this issue is to perform a large-scale meta-analysis of microarray data in the public domain[@b12].

In this study, 11 microarray datasets from tissue samples irradiated by γ--rays were retrieved from the Gene Expression Omnibus (GEO) and utilized as an integrated training set. A set of 29 biomarkers associated with different radiation doses was identified based on several criteria, such as Student\'s *t*-test and resampling tests. Furthermore, a machine learning algorithm, called support vector machine (SVM), was used to develop a prediction model based on the genes\' expression ratios. More than 80% accuracy was shown in classifying samples treated with higher and/or lower doses of radiation using 10,000 repetitions of 10-fold cross-validation in the training set. The prediction model showed similar accuracy in four independent datasets, suggesting its potential application to predict radiation doses across different studies.

Methods
=======

Data collection and pre-processing
----------------------------------

A protocol to identify differentially expressed (DE) genes associated with radiation dosage is illustrated in [Figure 1](#f1){ref-type="fig"}. A total of 11 microarray datasets retrieved from the GEO[@b13] were utilized as the training set ([Table 1](#t1){ref-type="table"}). To reduce the effects of confounding factors, only samples irradiated with γ--rays and collected 4--8 hours after radiation exposure were included. Furthermore, distinct cell lines were considered as different signatures and analyzed separately. Two pre-processing steps, including log~2~ transformation and quantile normalization, were performed to eliminate systematic biases across different platforms.

Identification of biomarkers associated with different radiation doses
----------------------------------------------------------------------

Based on the radiation dosage, each microarray was classified as higher (≥8 Gy) or lower (≤2 Gy) dose. To reduce redundancy and difficulty in processing multiple probes targeting the same gene, only probes with the largest coefficient of variation (CV) were retained for further analyses. Student\'s *t*-test was performed to compare the gene expression levels in radiation-treated cells to those in untreated cells. The estimated false discovery rate (*Q*-value) was computed to address the issue of multiple test correction and only those genes with *Q*-values \<0.1 were selected[@b12][@b14]. The formula for calculating *Q*-value is *Q* = (P\*N)/I, where P is the *P*-value from the *t*-test, N is the total number of genes, and I is the ranking of the *P*-value among N ([Figure 1](#f1){ref-type="fig"}: Step 2.1).

To exclude genes identified by chance, a resampling test was performed[@b12]. The number of DE genes for each signature was set from previous analyses, but genes in each DE signature were randomly selected. We repeated this procedure 10,000 times and tallied the number of signatures that each gene was selected as a DE gene to establish a null baseline. In other words, a null baseline of identifying one gene as a DE gene in the number of signatures was simulated after 10,000 repetitions. In this way, an empirical *P*-value for each gene was determined according to its number of significance in multiple signatures versus the null baseline. Only genes with empirical *P*-values less than 0.05 were included for the following analyses ([Figure 1](#f1){ref-type="fig"}: Step 2.2).

To consider multiple signatures simultaneously, we adopted an approach to estimate the minimum meta-false discovery rate (mFDR~MIN~)[@b12] as shown in the following equation: where S denotes the number of signatures, E~i~ denotes the number of DE genes selected at random, and N~i~ denotes the number of DE genes present in the ith signature, respectively. This measurement estimates the possibility of randomly identifying DE genes in multiple signatures ([Figure 1](#f1){ref-type="fig"}: Step 3.1). Lastly, Student\'s *t*-test was used to select biomarkers showing significant differences between microarrays exposed to higher or lower dose radiation ([Figure 1](#f1){ref-type="fig"}: Step 3.2, *P* \< 0.05).

Development of a prediction model using support vector machine
--------------------------------------------------------------

After identification of the DE genes associated with radiation dosage, a machine learning algorithm, SVM[@b15], was utilized to develop a classifier for predicting the radiation exposure of tissue samples ([Figure 1](#f1){ref-type="fig"}: Step 4). For each biomarker identified in Step 3.2, the ratio of gene expression levels between radiation treated and untreated cells was used as an input variable for the SVM model. As shown in [Table 1](#t1){ref-type="table"}, for the samples treated with higher radiation dose, GSE26835 has 362 samples compared to only 23 samples in total from the other four datasets (GSE36720, GSE8917, GSE35372, GSE30043). In order to compensate the imbalanced sample size, we randomly selected 23 samples from dataset GSE26835, and combined them with the 23 samples from the other four datasets to develop the prediction model. A 10-fold cross-validation was performed for 10,000 iterations to calculate the accuracy and stability of prediction performance in the training samples. In addition, the reproducibility of the proposed classifier in independent datasets was evaluated by using several microarrays collected at different time points after irradiation ([Table S1](#s1){ref-type="supplementary-material"}).

Results
=======

Identification of biomarkers associated with radiation dosage
-------------------------------------------------------------

As shown in [Figure 1](#f1){ref-type="fig"}, several filtering and selection steps were utilized to identify DE genes associated with radiation dosage. A signature was defined as one set of genes summarized from one cell line or one dataset. The results of Student\'s *t*-test (Step 2.1) showed that 5,949 genes in the higher-dose group and 11,413 genes in the lower-dose group had differential expression in at least one signature. To address multiple hypothesis testing and concurrently integrate different signatures, a resampling test following Rhodes\'s study[@b12] was adopted and repeated 10,000 times (Step 2.2). As shown in [Table 2](#t2){ref-type="table"}, only 502 and 697 genes were found to be significantly DE (*P* \< 0.05) in response to higher or lower doses of radiation. These results showed that more than 90% of the DE genes identified in Step 2.1 were excluded due to their high possibility of being selected randomly, suggesting that such a resampling test (Step 2.2) is useful to exclude false positive genes.

Next, we utilized an approach called mFDR~MIN~ to determine the cutoff value of a biomarker in multiple signatures ([Figure 1](#f1){ref-type="fig"}, Step 3.1). This study aimed to develop a prediction model, and large numbers of biomarkers would make it difficult to use the model for practical applications. Therefore, to considering the issues of practicability and false positive rates simultaneously, we determined that a biomarker must be identified in at least five signatures in response to higher-dose radiation and three signatures in response to lower-dose ([Table 2](#t2){ref-type="table"}). This cutoff of significance in multiple signatures was determined based on the low mFDR (*Q* ≤ 0.3) and an acceptable number of biomarkers (N \< 100). The results indicated that 35 genes in higher dose and 51 genes in lower dose were significantly different from untreated cells ([Table 3](#t3){ref-type="table"}). Among them, Student\'s *t*-test was performed to exclude genes having no differences in expression in response to higher and lower doses of radiation ([Figure 1](#f1){ref-type="fig"}, Step 3.2; *P* \< 0.05). A set of 29 biomarkers showed significant differences at both higher and lower radiation doses, and thus all 29 biomarkers were included for developing the prediction model ([Table 3](#t3){ref-type="table"}).

Internal 10-fold cross-validation of the 29 biomarkers
------------------------------------------------------

After identifying the final set of 29 biomarkers, a prediction model was developed based on the ratios of gene expression in radiation treated versus untreated cells using the SVM algorithm. A 10-fold cross-validation was repeated 10,000 times to evaluate the prediction performance and consistency in the training samples. As shown in [Figure 2A](#f2){ref-type="fig"}, the average values of accuracy in the training samples were approximately 0.9 for the identified 29 biomarkers. The standard deviations were only around 0.03 for the 10,000 repetitions, suggesting that the prediction performances of the 29 biomarkers were highly consistent, even if the 23 samples from GSE26835 were used. In addition, a 10-fold cross-validation was performed by using all 419 samples shown in [Table 1](#t1){ref-type="table"}, and the prediction accuracy (0.86) was highly similar to that obtained from using 80 training samples. Therefore, these results demonstrated that the prediction model based on the 29 biomarkers was accurate in classifying samples treated with higher versus lower radiation doses.

Comparisons with published signatures
-------------------------------------

To further evaluate the 29 biomarkers, their predictive performance was also compared with two published signatures for predicting radiation dosage[@b7][@b8]. Only the genes that existed in the training samples and showed no missing values were included in the analysis ([Table S2](#s1){ref-type="supplementary-material"}). The same 10-fold cross-validation approach described previously was performed to investigate their performance. The 29 biomarkers identified in our approach showed significantly (*P* \<0.05) better accuracy than the other two signatures ([Figure 2A](#f2){ref-type="fig"}). Notably, the standard deviations were also not high for the two published studies and thus the random selection of samples in GSE26835 was not a critical factor in affecting the prediction performance.

External evaluations of the 29 biomarkers in independent datasets
-----------------------------------------------------------------

To validate the prediction performance of the 29 biomarkers and the two published signatures, four microarray datasets collected within 3--6 hours after irradiation treatments were examined ([Table S1](#s1){ref-type="supplementary-material"}). As described previously, a total of 10,000 analyses were performed to calculate the accuracy. The results are summarized in [Figure 2B](#f2){ref-type="fig"}, which shows that the 29 biomarkers identified in this study were significantly better predictors than the genes obtained from Paul\'s study. The accuracy of the 29 biomarkers in the samples treated with higher-dose radiation was similar to that of the meta-genes obtained from Dressman\'s study. However, compared with the 29 identified biomarkers, Dressman\'s genes showed poor performance in the prediction of the samples treated with lower-dose radiation. The 29 identified biomarkers showed around 90% accuracy in classifying samples treated with higher-dose radiation, 65% accuracy in lower-dose radiation samples, and 83% accuracy overall.

Functional characterization of the 29 biomarkers
------------------------------------------------

Ingenuity pathway analysis was used to explore possible upstream regulators and characterize associated biological pathways of the 29 biomarkers ([Table S3](#s1){ref-type="supplementary-material"}). As shown in [Figure 3](#f3){ref-type="fig"}, 19 out of the 29 biomarkers can be regulated by three genes including *TP53*, *FOXM1*, and *ERBB2.* All three regulators have been reported to have pivotal roles in modulating radiation responses[@b16][@b17][@b18]. In addition to transcription regulators, two major biological pathways---cell cycle regulation and the pyrimidine salvage pathway---were significantly enriched (*P* \< 0.01). Several studies also have shown that irradiation is able to cause transcriptional changes in genes involved in these two functions[@b16][@b19][@b20], suggesting that the 29 biomarkers not only can be used for predicting radiation doses but also participate in important functions in response to radiation exposure.

Discussion
==========

A large-scale radiation emergency may affect many people at one time, and thus how to efficiently and accurately measure radiation exposure becomes an important issue. Several studies have identified predictive biomarkers for radiation dose using gene expression microarrays[@b7][@b8][@b9]. However, the generalizability (i.e., reproducibility) of those reported biomarkers was not evaluated and validated in external independent datasets, which makes them difficult to apply. To address this issue, this study developed a meta-analysis flowchart to select biomarkers across independent microarray datasets. The 29 identified biomarkers had approximately 90% accuracy in the training samples, which were composed of 11 datasets, and had more than 80% accuracy in four independent datasets, suggesting the effectiveness of our proposed method.

Two different approaches can be used to identify biomarkers for predicting radiation exposure across independent datasets. One possibility is to select one dataset as the training set and then validate the identified biomarkers in external samples[@b21][@b22]. Notably, the most important limitation of such an approach is that a dataset with a large sample size is required because potential biomarkers are selected based solely on it. However, the sizes of irradiated microarray datasets that are available in the published domain are usually not very large, which makes this approach difficult to execute. In addition, most of these datasets were investigated by distinct platforms, including both one-color and two-color systems. Challenges arise when trying to merge those datasets into one integrated meta-dataset due to their huge discrepancy and systematic biases. Therefore, we chose an alternative approach ([Figure 1](#f1){ref-type="fig"}) in which multiple datasets were considered individually.

The 29 biomarkers identified by our methods were compared with two published sets of biomarkers shown in [Table S2](#s1){ref-type="supplementary-material"}. Six and zero of the 29 biomarkers were in common with those obtained from Paul\'s study and Dressman\'s study, respectively, illustrating the fact that biomarkers identified in one microarray dataset rarely overlap with those reported in other studies[@b11]. As shown in [Figure 2](#f2){ref-type="fig"}, the prediction performance of the 29 biomarkers was generally higher than that of Paul\'s and Dressman\'s studies, except the accuracy of external samples treated with higher radiation dose (91% in our study versus 95% in Dressman\'s). Notably, Dressman\'s biomarkers showed much better performance in classifying samples treated with higher radiation doses than classifying those with lower doses. One possible reason for this imbalance is that most of their original samples were irradiated with 200-1,350 cGy, which fell primarily into the higher radiation dose group in the current study. Since radiation doses in future samples are unknown, a balanced prediction performance is more practical for real-world applications.

There are some limitations of the prediction model developed in this study. First, the collection of microarray datasets analyzed in this study included only samples that were treated with γ--rays and harvested 3--8 hours later. It is well known that the radiation source plays an important role in driving downstream gene expression, and different signaling pathways are triggered in response to the different types of irradiation[@b23][@b24]. In addition, dissimilar genes and biological functions are induced in cells at different time points after radiation exposure[@b25][@b26]. To reduce potential variations in gene expression levels, a unified radiation source (γ--ray) and post-irradiation time period (3--6 hours) were utilized in the analyses. Therefore, the prediction model only showed about 55% accuracy in identifying radiation dose in samples harvested 24 hours after irradiation ([Figure S1](#s1){ref-type="supplementary-material"}), suggesting this model is useful in classifying radiation exposures during the early-response period but not the late-response period. Furthermore, the prediction model classified samples into higher or lower radiation dose groups, instead of numerically estimating their exposed radiation dose. Although specific definition of exposed radiation dose in samples may provide better classification performance, the sizes of published irradiated microarrays are not sufficient to develop a prediction model. Meanwhile, some variations in gene expression levels were still observed, even if the samples were reclassified in the opposite group, especially the lower-dose ones. This may be attributed to the fact that transcriptional changes in response to radiation are not linear, and genes may be switched on/off after a certain threshold of radiation exposure[@b1][@b27]. However, more samples irradiated by different doses are required to develop a regression model across independent datasets.

Analyses of upstream regulators ([Figure 3](#f3){ref-type="fig"}) and biological functions were performed to elucidate how the 29 biomarkers participate in the radiation response. Unsurprisingly, *TP53* was a consistently significant regulator (*P* \< 10^−10^) in the three-biomarker sets for samples treated with higher and/or lower radiation doses ([Table S4](#s1){ref-type="supplementary-material"}). A previous report demonstrated that inhibition of *FOXM1* expression can elevate radiation sensitivity in cells after 8 or 10 Gy γ--ray irradiation[@b17], which is consistent with our finding that *FOXM1* was the most significant regulator (*P* = 2.04 \* 10^−20^) after higher-dose radiation exposure. As the second most significant regulator after higher-dose irradiation (*P* = 1.07 \* 10^−14^), *ERBB2* is able to reduce radiation induced apoptosis by activating NFκB-related signaling in cells exposed to 5 Gy[@b18]. In addition, the 29 biomarkers were significantly involved in cell cycle regulation and in the pyrimidine salvage pathway. Undoubtedly, the identified biomarkers were associated with these pathways because deoxyribonucleotide synthesis was observed in two irradiated cell lines with different radiosensitivities[@b20]. We conclude that these 29 biomarkers not only are regulated by well-known radiation modulators but also have important roles in response to radiation exposure.
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![Flowchart for identification of differentially expressed genes associated with radiation doses and development of a prediction model.\
The number of genes shown in the right dotted box denotes the union of genes across multiple signatures.](srep06293-f1){#f1}

![Prediction performance of the three sets of biomarkers.\
A 10-fold cross-validation was repeated 10,000 times and the accuracies in the samples treated with higher and/or lower radiation doses were plotted. (A) Training samples (46 higher-dose and 34 lower-dose). (B) External independent datasets (64 higher-dose and 30 lower-dose).](srep06293-f2){#f2}

![Gene-gene interaction networks of the 29 biomarkers.\
Three possible upstream regulators were enriched. Direct evidence between two genes from previous literature reports is shown as a solid line and indirect evidence is depicted as a dashed line.](srep06293-f3){#f3}

###### Characteristics of training samples

  Accession No.[a](#t1-fn1){ref-type="fn"}    Sample No.       Cell type       Dose (Gy)   Time after radiation (h)
  ------------------------------------------ ------------ ------------------- ----------- --------------------------
  GSE26835                                       362          Lymphoblast        10.0                 6
  GSE36720[b](#t1-fn2){ref-type="fn"}             9        LNCap, PC3, DU145     10.0                 6
  GSE8917                                         5        Peripheral blood       8.0                 6
  GSE35372                                        6            HL60, RV+          8.0                 4
  GSE30043                                        3               U87             8.5                 4
  GSE23515[c](#t1-fn3){ref-type="fn"}             12       Peripheral blood       2.0                 6
  GSE25772                                        4           Fibroblast          2.0                 8
  GSE30044[d](#t1-fn4){ref-type="fn"}             3               HEK             2.0                 4
  GSE8917                                         5        Peripheral blood       2.0                 6
  GSE6971                                         4           Fibroblast          1.5                 6
  GSE7075                                         6           Fibroblast          1.5                 6

^a^GEO accession number.

^b^Samples treated with multiple-fraction irradiation were excluded.

^c^Samples from smokers were excluded.

^d^Samples treated with DNA minor groove binding ligand were excluded.

###### Numbers of identified biomarkers in different steps in [Figure 1](#f1){ref-type="fig"}

           Higher Dose (≥8 Gy)   Lower Dose (≤2 Gy)                       
  ------- --------------------- -------------------- ------ ------- ----- ------
  8                 0                    0            \--     \--    \--   \--
  7                 1                    1            1.00    \--    \--   \--
  6                 5                    5            0.20     0      0    \--
  5                29                    29           0.03     1      1    1.00
  4                83                    83           0.01     6      6    0.16
  3                551                  258           0.53    44     44    0.02
  2               2,534                 126           0.95    603    595   0.01
  1               8,210                  0            1.00   5,295   51    0.99
  Total          11,413                 502                  5,949   697     

\#: Number; DE: differentially expressed; Sig: Significant; mFDR~MIN~: minimum meta-false discovery rate.

###### Identified biomarkers for samples treated by higher and/or lower radiation doses

  Group (Gene No.)                                                                                                                                                                                                                                                    Gene symbol
  ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Higher Dose (35)**                                                                                        *TPX2, ASPM*, *AURKB*, *CDCA3*, *CENPA*, *CENPF, AURKA*, *BIRC5*, *C12orf5*, *CCNB1*, *CCNF*, *CDC6*, *CDC20*, *CDCA2*, *CENPE*, *DLGAP5*, *E2F5*, *FAM83D*, *GTSE1*, *KIAA1333*, *KIF2C*, *KIF20A*, *MTIF2*, *MXD3*, *NDC80*, *NEK2*, *NIF3L1*, *PLK1*, *PRR11*, *PSRC1*, *RAD54L*, *RFC5*, *SPTBN1*, *TMEM19*, *TNFRSF10B*
  **Lower Dose (51)**            *CDKN1A, FDXR*, *FHL2*, *GADD45A*, *MYC*, *TP53I3*, *TRIAP1, ACAP1*, *AEN*, *AFF1*, *APOBEC3H*, *BLOC1S2*, *BST1*, *C12orf5*, *C13orf30*, *C14orf128*, *COL27A1*, *CPT2*, *DDB2*, *ECHDC1*, *FANCE*, *FBXL4*, *FXYD2*, *GRIA1*, *IGFBP7*, *JAM2*, *LY9*, *MCM3*, *MDM2*, *MSH6*, *NMT2*, *NSRP1*, *NSUN7*, *PHLDA3*, *PITHD1*, *PLK2*, *PLK3*, *REV3L*, *RPS27L*, *SAP30*, *SESN1*, *SESN2*, *SLBP*, *SLFN11*, *SS18L2*, *TNFRSF10B*, *TNFSF4*, *TRIM22*, *VWCE*, *WHSC1L1*, *ZDHHC14*
  **High and Low Doses (29)**                                                                                                                   *AEN*, *ASPM*, *AURKB*, *BIRC5*, *CCNB1*, *CCNF*, *CDC20*, *CDCA3*, *CENPA*, *CENPE*, *CENPF*, *DLGAP5*, *FBXL4*, *FDXR*, *FHL2*, *GTSE1*, *KIF20A*, *KIF2C*, *LY9*, *MXD3*, *NDC80*, *NEK2*, *PLK1*, *PLK2*, *PSRC1*, *RPS27L*, *SESN1*, *SLBP*, *TPX2*
